L3MBTL2

Across TCGA pan-cancer cohorts, L3MBTL2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated L3MBTL2 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher L3MBTL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated L3MBTL2 expression acts as an unfavorable survival marker.

OV, HNSC, and LGG are the cancer types where L3MBTL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.140	0.541	.001	18	view →
HNSC	DFS	Median	All	0.159	0.626	.015	12	view →
LGG	DFS	Median	All	0.110	0.826	<.001	6	view →
PRAD	DFS	Median	All	0.113	0.935	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

L3MBTL2–OV (DFS)

Open the OV breakdown →